| DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
| Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[37] |
| Sodium bicarbonate |
DMMU6BJ
|
Minor |
as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by Sodium bicarbonate mediated altered urine pH. |
Acidosis [5C73]
|
[38] |
| Tromethamine |
DMOBLGK
|
Minor |
as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by Tromethamine mediated altered urine pH. |
Acidosis [5C73]
|
[38] |
| Tretinoin |
DM49DUI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tretinoin. |
Acne vulgaris [ED80]
|
[39] |
| Isotretinoin |
DM4QTBN
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Isotretinoin. |
Acne vulgaris [ED80]
|
[39] |
| Nicotinamide |
DMUPE07
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Nicotinamide. |
Acquired cutaneous blood vessel malformation [EF20]
|
[39] |
| Pioglitazone |
DMKJ485
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Pioglitazone. |
Acute diabete complication [5A2Y]
|
[39] |
| Midostaurin |
DMI6E0R
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[39] |
| Arn-509 |
DMT81LZ
|
Moderate |
Accelerated clearance of Methotrexate due to the transporter induction by Arn-509. |
Acute myeloid leukaemia [2A60]
|
[39] |
| Gilteritinib |
DMTI0ZO
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[39] |
| Framycetin |
DMF8DNE
|
Moderate |
Altered absorption of Methotrexate caused by Framycetin. |
Alcoholic liver disease [DB94]
|
[40] |
| Oxandrolone |
DMU9MYJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Oxandrolone. |
Alcoholic liver disease [DB94]
|
[39] |
| Paromomycin |
DM1AGXN
|
Moderate |
Altered absorption of Methotrexate caused by Paromomycin. |
Amoebiasis [1A36]
|
[40] |
| Inotersen |
DMJ93CT
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Inotersen. |
Amyloidosis [5D00]
|
[39] |
| Dronedarone |
DMA8FS5
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Dronedarone. |
Angina pectoris [BA40]
|
[39] |
| Bedaquiline |
DM3906J
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[41] |
| Oxymetholone |
DMFXUT8
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Oxymetholone. |
Aplastic anaemia [3A70]
|
[39] |
| Voriconazole |
DMAOL2S
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Voriconazole. |
Aspergillosis [1F20]
|
[39] |
| Posaconazole |
DMUL5EW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Posaconazole. |
Aspergillosis [1F20]
|
[39] |
| Budesonide |
DMJIBAW
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Budesonide. |
Asthma [CA23]
|
[42] |
| Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Roflumilast. |
Asthma [CA23]
|
[39] |
| Zileuton |
DMVRIC2
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Zileuton. |
Asthma [CA23]
|
[39] |
| Kanamycin |
DM2DMPO
|
Moderate |
Altered absorption of Methotrexate caused by Kanamycin. |
Bacterial infection [1A00-1C4Z]
|
[40] |
| Clavulanate |
DM2FGRT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Clavulanate. |
Bacterial infection [1A00-1C4Z]
|
[39] |
| Clarithromycin |
DM4M1SG
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Clarithromycin. |
Bacterial infection [1A00-1C4Z]
|
[39] |
| Ticarcillin |
DM4ME02
|
Major |
Decreased elimination of Methotrexate caused by Ticarcillin mediated competitive inhibition of renal tubular secretion. |
Bacterial infection [1A00-1C4Z]
|
[43] |
| Sulfamethoxazole |
DMB08GE
|
Moderate |
Increased plasma concentration of Methotrexate and Sulfamethoxazole due to competitive binding of plasma proteins. |
Bacterial infection [1A00-1C4Z]
|
[44] |
| Meticillin |
DMIKHN0
|
Major |
Decreased elimination of Methotrexate caused by Meticillin mediated competitive inhibition of renal tubular secretion. |
Bacterial infection [1A00-1C4Z]
|
[45] |
| Oxytetracycline |
DMOVH1M
|
Moderate |
Increased plasma concentration of Methotrexate and Oxytetracycline due to competitive binding of plasma proteins. |
Bacterial infection [1A00-1C4Z]
|
[46] |
| Bacampicillin |
DMP54C7
|
Major |
Decreased elimination of Methotrexate caused by Bacampicillin mediated competitive inhibition of renal tubular secretion. |
Bacterial infection [1A00-1C4Z]
|
[43] |
| Oxacillin |
DMTAFY4
|
Major |
Decreased elimination of Methotrexate caused by Oxacillin mediated competitive inhibition of renal tubular secretion. |
Bacterial infection [1A00-1C4Z]
|
[43] |
| Cloxacillin |
DMUTL7O
|
Major |
Decreased elimination of Methotrexate caused by Cloxacillin mediated competitive inhibition of renal tubular secretion. |
Bacterial infection [1A00-1C4Z]
|
[43] |
| Amoxicillin |
DMUYNEI
|
Major |
Decreased elimination of Methotrexate caused by Amoxicillin mediated competitive inhibition of renal tubular secretion. |
Bacterial infection [1A00-1C4Z]
|
[43] |
| Minocycline |
DMVN5OH
|
Moderate |
Increased plasma concentration of Methotrexate and Minocycline due to competitive binding of plasma proteins. |
Bacterial infection [1A00-1C4Z]
|
[46] |
| Telithromycin |
DMZ4P3A
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Telithromycin. |
Bacterial infection [1A00-1C4Z]
|
[39] |
| Tetracycline |
DMZA017
|
Moderate |
Increased plasma concentration of Methotrexate and Tetracycline due to competitive binding of plasma proteins. |
Bacterial infection [1A00-1C4Z]
|
[46] |
| Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Methotrexate and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[47] |
| Lomustine |
DMMWSUL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Lomustine. |
Brain cancer [2A00]
|
[39] |
| Lapatinib |
DM3BH1Y
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Lapatinib. |
Breast cancer [2C60-2C6Y]
|
[39] |
| LY2835219 |
DM93VBZ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Pralatrexate |
DMAO80I
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Pralatrexate. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Tucatinib |
DMBESUA
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tucatinib. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Tamoxifen |
DMLB0EZ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tamoxifen. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Bosutinib |
DMTI8YE
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Trastuzumab Emtansine |
DMU1LXS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Trastuzumab Emtansine. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Fluoxymesterone |
DMUHCF1
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Fluoxymesterone. |
Breast cancer [2C60-2C6Y]
|
[39] |
| Demeclocycline |
DMZEPFJ
|
Moderate |
Increased plasma concentration of Methotrexate and Demeclocycline due to competitive binding of plasma proteins. |
Bronchitis [CA20]
|
[46] |
| Atorvastatin |
DMF28YC
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Atorvastatin. |
Cardiovascular disease [BA00-BE2Z]
|
[39] |
| Fenofibric acid |
DMGO2MC
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Fenofibric acid. |
Cardiovascular disease [BA00-BE2Z]
|
[39] |
| Macitentan |
DMP79A1
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Macitentan. |
Cardiovascular disease [BA00-BE2Z]
|
[39] |
| Chenodiol |
DMQ8JIK
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Chenodiol. |
Cholelithiasis [DC11]
|
[39] |
| Iodipamide |
DMXIQYS
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Iodipamide. |
Cholelithiasis [DC11]
|
[48] |
| Corticotropin |
DMP9TWZ
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Corticotropin. |
Chronic kidney disease [GB61]
|
[42] |
| Phenylbutazone |
DMAYL0T
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Phenylbutazone. |
Chronic pain [MG30]
|
[49] |
| Ketoprofen |
DMRKXPT
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Ketoprofen. |
Chronic pain [MG30]
|
[49] |
| Regorafenib |
DMHSY1I
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Regorafenib. |
Colorectal cancer [2B91]
|
[37] |
| Intedanib |
DMSTA36
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Intedanib. |
Colorectal cancer [2B91]
|
[39] |
| Methoxyflurane |
DML0RAE
|
Moderate |
Increased risk of nephrotoxicity by the combination of Methotrexate and Methoxyflurane. |
Corneal disease [9A76-9A78]
|
[39] |
| Pasireotide |
DMHM7JS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Pasireotide. |
Cushing syndrome [5A70]
|
[39] |
| Ivacaftor |
DMZC1HS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ivacaftor. |
Cystic fibrosis [CA25]
|
[39] |
| Ethanol |
DMDRQZU
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ethanol. |
Cystitis [GC00]
|
[39] |
| Nefazodone |
DM4ZS8M
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Nefazodone. |
Depression [6A70-6A7Z]
|
[39] |
| Milnacipran |
DMBFE74
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Milnacipran. |
Depression [6A70-6A7Z]
|
[39] |
| Polatuzumab vedotin |
DMF6Y0L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Polatuzumab vedotin. |
Diffuse large B-cell lymphoma [2A81]
|
[39] |
| PMID28454500-Compound-96 |
DM2A75P
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and PMID28454500-Compound-96. |
Discovery agent [N.A.]
|
[39] |
| SODIUM CITRATE |
DMHPD2Y
|
Minor |
as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by SODIUM CITRATE mediated altered urine pH. |
Discovery agent [N.A.]
|
[38] |
| Benzylpenicillin |
DMS9503
|
Major |
Decreased elimination of Methotrexate caused by Benzylpenicillin mediated competitive inhibition of renal tubular secretion. |
Discovery agent [N.A.]
|
[45] |
| Felbamate |
DM1V5ZS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Felbamate. |
Epilepsy/seizure [8A61-8A6Z]
|
[39] |
| Fosphenytoin |
DMOX3LB
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Fosphenytoin. |
Epilepsy/seizure [8A61-8A6Z]
|
[39] |
| Ethotoin |
DMXWOCP
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ethotoin. |
Epilepsy/seizure [8A61-8A6Z]
|
[39] |
| Carbamazepine |
DMZOLBI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Carbamazepine. |
Epilepsy/seizure [8A61-8A6Z]
|
[39] |
| Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[39] |
| Mefenamic acid |
DMK7HFI
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Mefenamic acid. |
Female pelvic pain [GA34]
|
[49] |
| Dantrolene |
DM1D8XY
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Dantrolene. |
Fever [MG26]
|
[39] |
| Itraconazole |
DMCR1MV
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Itraconazole. |
Fungal infection [1F29-1F2F]
|
[39] |
| Terbinafine |
DMI6HUW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Terbinafine. |
Fungal infection [1F29-1F2F]
|
[39] |
| Ketoconazole |
DMPZI3Q
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ketoconazole. |
Fungal infection [1F29-1F2F]
|
[39] |
| Amphotericin B |
DMTAJQE
|
Moderate |
Increased risk of nephrotoxicity by the combination of Methotrexate and Amphotericin B. |
Fungal infection [1F29-1F2F]
|
[37] |
| Atovaquone |
DMY4UMW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Atovaquone. |
Fungal infection [1F29-1F2F]
|
[39] |
| Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[39] |
| Lamivudine |
DMI347A
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Lamivudine. |
Hepatitis virus infection [1E50-1E51]
|
[39] |
| 177Lu-DOTATATE |
DMT8GVU
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[39] |
| Rifampin |
DMA8J1G
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Rifampin. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[39] |
| Fostemsavir |
DM50ILT
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[50] |
| Stavudine |
DM6DEK9
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Stavudine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Tipranavir |
DM8HJX6
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tipranavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Emtricitabine |
DMBMUWZ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Emtricitabine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Efavirenz |
DMC0GSJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Efavirenz. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Zalcitabine |
DMH7MUV
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Zalcitabine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Abacavir |
DMMN36E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Abacavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Darunavir |
DMN3GCH
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Darunavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Maraviroc |
DMTL94F
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Maraviroc. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Bempedoic acid |
DM1CI9R
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Bempedoic acid. |
Hyper-lipoproteinaemia [5C80]
|
[51] |
| Simvastatin |
DM30SGU
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Simvastatin. |
Hyper-lipoproteinaemia [5C80]
|
[39] |
| Fluvastatin |
DM4MDJY
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Fluvastatin. |
Hyper-lipoproteinaemia [5C80]
|
[39] |
| Fenofibrate |
DMFKXDY
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Fenofibrate. |
Hyper-lipoproteinaemia [5C80]
|
[39] |
| Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Methotrexate and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[52] |
| Rosuvastatin |
DMMIQ7G
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Rosuvastatin. |
Hyper-lipoproteinaemia [5C80]
|
[39] |
| Teriflunomide |
DMQ2FKJ
|
Major |
Increased risk of hepatotoxicity by the combination of Methotrexate and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[53] |
| BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Methotrexate and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[54] |
| Moexipril |
DM26E4B
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Moexipril. |
Hypertension [BA00-BA04]
|
[39] |
| Captopril |
DM458UM
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Captopril. |
Hypertension [BA00-BA04]
|
[39] |
| Methyldopa |
DM5I621
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Methyldopa. |
Hypertension [BA00-BA04]
|
[39] |
| Labetalol |
DMK8U72
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Labetalol. |
Hypertension [BA00-BA04]
|
[39] |
| Enalapril |
DMNFUZR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Enalapril. |
Hypertension [BA00-BA04]
|
[39] |
| Perindopril |
DMOPZDT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Perindopril. |
Hypertension [BA00-BA04]
|
[39] |
| Quinapril |
DMR8H31
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Quinapril. |
Hypertension [BA00-BA04]
|
[39] |
| Sodium acetate anhydrous |
DMH21E0
|
Minor |
as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Methotrexate caused by Sodium acetate anhydrous mediated altered urine pH. |
Hypo-osmolality/hyponatraemia [5C72]
|
[38] |
| Tolvaptan |
DMIWFRL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tolvaptan. |
Hypo-osmolality/hyponatraemia [5C72]
|
[39] |
| Fludrocortisone |
DMUDIR8
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Fludrocortisone. |
Hypo-osmolality/hyponatraemia [5C72]
|
[42] |
| Pirfenidone |
DM6VZFQ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Pirfenidone. |
Idiopathic interstitial pneumonitis [CB03]
|
[39] |
| Vitamin B3 |
DMQVRZH
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Vitamin B3. |
Inborn lipid metabolism error [5C52]
|
[39] |
| Givosiran |
DM5PFIJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Givosiran. |
Inborn porphyrin/heme metabolism error [5C58]
|
[39] |
| Febuxostat |
DMDEXQ0
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Febuxostat. |
Inborn purine/pyrimidine/nucleotide metabolism error [5C55]
|
[39] |
| Balsalazide |
DM7I1T9
|
Moderate |
Increased risk of nephrotoxicity by the combination of Methotrexate and Balsalazide. |
Indeterminate colitis [DD72]
|
[55] |
| Meclofenamic acid |
DM05FXR
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Meclofenamic acid. |
Inflammatory spondyloarthritis [FA92]
|
[56] |
| Testosterone |
DM7HUNW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Testosterone. |
Low bone mass disorder [FB83]
|
[39] |
| Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Denosumab. |
Low bone mass disorder [FB83]
|
[57] |
| Porfimer Sodium |
DM7ZWNY
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Methotrexate and Porfimer Sodium. |
Lung cancer [2C25]
|
[58] |
| Ceritinib |
DMB920Z
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ceritinib. |
Lung cancer [2C25]
|
[39] |
| Lurbinectedin |
DMEFRTZ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Lurbinectedin. |
Lung cancer [2C25]
|
[39] |
| BIBW 2992 |
DMTKD7Q
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and BIBW 2992. |
Lung cancer [2C25]
|
[39] |
| Pralsetinib |
DMWU0I2
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Pralsetinib. |
Lung cancer [2C25]
|
[39] |
| Capmatinib |
DMYCXKL
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Capmatinib. |
Lung cancer [2C25]
|
[59] |
| Selpercatinib |
DMZR15V
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Selpercatinib. |
Lung cancer [2C25]
|
[39] |
| Sulphadoxine |
DMZI2UF
|
Moderate |
Increased plasma concentration of Methotrexate and Sulphadoxine due to competitive binding of plasma proteins. |
Malaria [1F40-1F45]
|
[44] |
| Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[39] |
| Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[60] |
| Idelalisib |
DM602WT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[61] |
| IPI-145 |
DMWA24P
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and IPI-145. |
Mature B-cell leukaemia [2A82]
|
[39] |
| Clofarabine |
DMCVJ86
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[62] |
| Blinatumomab |
DMGECIJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[39] |
| Mercaptopurine |
DMTM2IK
|
Minor |
Decreased metabolism of Methotrexate caused by Mercaptopurine. |
Mature B-cell lymphoma [2A85]
|
[63] |
| Ponatinib |
DMYGJQO
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[39] |
| Cytarabine |
DMZD5QR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Cytarabine. |
Mature B-cell lymphoma [2A85]
|
[37] |
| Arry-162 |
DM1P6FR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Arry-162. |
Melanoma [2C30]
|
[39] |
| Vemurafenib |
DM62UG5
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Vemurafenib. |
Melanoma [2C30]
|
[39] |
| Ipilimumab |
DMJTIYK
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ipilimumab. |
Melanoma [2C30]
|
[39] |
| Dacarbazine |
DMNPZL4
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Dacarbazine. |
Melanoma [2C30]
|
[39] |
| Danazol |
DML8KTN
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Danazol. |
Menstrual cycle bleeding disorder [GA20]
|
[39] |
| Lasmiditan |
DMXLVDT
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Lasmiditan. |
Migraine [8A80]
|
[64] |
| Exjade |
DMHPRWG
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Exjade. |
Mineral absorption/transport disorder [5C64]
|
[65] |
| Riluzole |
DMECBWN
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Riluzole. |
Motor neuron disease [8B60]
|
[39] |
| Carfilzomib |
DM48K0X
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Carfilzomib. |
Multiple myeloma [2A83]
|
[39] |
| Panobinostat |
DM58WKG
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Panobinostat. |
Multiple myeloma [2A83]
|
[39] |
| Thalidomide |
DM70BU5
|
Major |
Additive thrombogenic effects by the combination of Methotrexate and Thalidomide. |
Multiple myeloma [2A83]
|
[66] |
| Tecfidera |
DM2OVDT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tecfidera. |
Multiple sclerosis [8A40]
|
[39] |
| Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Methotrexate and Siponimod. |
Multiple sclerosis [8A40]
|
[37] |
| Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Methotrexate and Fingolimod. |
Multiple sclerosis [8A40]
|
[67] |
| Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[68] |
| Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Methotrexate and Ozanimod. |
Multiple sclerosis [8A40]
|
[39] |
| Nilotinib |
DM7HXWT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[39] |
| Imatinib |
DM7RJXL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Imatinib. |
Myeloproliferative neoplasm [2A20]
|
[39] |
| Rolapitant |
DM8XP26
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Rolapitant. |
Nausea/vomiting [MD90]
|
[69] |
| Bupropion |
DM5PCS7
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Bupropion. |
Nicotine use disorder [6C4A]
|
[39] |
| Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[39] |
| Orlistat |
DMRJSP8
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Orlistat. |
Obesity [5B80-5B81]
|
[39] |
| Valdecoxib |
DMAY7H4
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Valdecoxib. |
Osteoarthritis [FA00-FA05]
|
[39] |
| Diclofenac |
DMPIHLS
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Diclofenac. |
Osteoarthritis [FA00-FA05]
|
[49] |
| Naproxen |
DMZ5RGV
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Naproxen. |
Osteoarthritis [FA00-FA05]
|
[49] |
| Rucaparib |
DM9PVX8
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Rucaparib. |
Ovarian cancer [2C73]
|
[70] |
| Etodolac |
DM6WJO9
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Etodolac. |
Pain [MG30-MG3Z]
|
[49] |
| Ibuprofen |
DM8VCBE
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Ibuprofen. |
Pain [MG30-MG3Z]
|
[49] |
| Pemetrexed |
DMMX2E6
|
Moderate |
Decreased renal excretion of Methotrexate caused by Pemetrexed mediated nephrotoxicity. |
Pleural mesothelioma [2C26]
|
[71] |
| Prednisone |
DM2HG4X
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Prednisone. |
Postoperative inflammation [1A00-CA43]
|
[42] |
| Hydrocortisone |
DMGEMB7
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Hydrocortisone. |
Postoperative inflammation [1A00-CA43]
|
[42] |
| Bromfenac |
DMKB79O
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Bromfenac. |
Postoperative inflammation [1A00-CA43]
|
[49] |
| ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and ABIRATERONE. |
Prostate cancer [2C82]
|
[39] |
| Nilutamide |
DMFN07X
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Nilutamide. |
Prostate cancer [2C82]
|
[39] |
| Darolutamide |
DMV7YFT
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Darolutamide. |
Prostate cancer [2C82]
|
[72] |
| Bicalutamide |
DMZMSPF
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Bicalutamide. |
Prostate cancer [2C82]
|
[39] |
| Ambrisentan |
DMD1QXW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Ambrisentan. |
Pulmonary hypertension [BB01]
|
[39] |
| Axitinib |
DMGVH6N
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Axitinib. |
Renal cell carcinoma [2C90]
|
[39] |
| Temsirolimus |
DMS104F
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Temsirolimus. |
Renal cell carcinoma [2C90]
|
[73] |
| Meloxicam |
DM2AR7L
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Meloxicam. |
Rheumatoid arthritis [FA20]
|
[49] |
| Sulindac |
DM2QHZU
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Sulindac. |
Rheumatoid arthritis [FA20]
|
[49] |
| Tocilizumab |
DM7J6OR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tocilizumab. |
Rheumatoid arthritis [FA20]
|
[39] |
| Canakinumab |
DM8HLO5
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Canakinumab. |
Rheumatoid arthritis [FA20]
|
[74] |
| Oxaprozin |
DM9UB0P
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Oxaprozin. |
Rheumatoid arthritis [FA20]
|
[49] |
| Rilonacept |
DMGLUQS
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Rilonacept. |
Rheumatoid arthritis [FA20]
|
[74] |
| Golimumab |
DMHZV7X
|
Major |
Additive immunosuppressive effects by the combination of Methotrexate and Golimumab. |
Rheumatoid arthritis [FA20]
|
[75] |
| Sulfasalazine |
DMICA9H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Sulfasalazine. |
Rheumatoid arthritis [FA20]
|
[39] |
| Fenoprofen |
DML5VQ0
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Fenoprofen. |
Rheumatoid arthritis [FA20]
|
[49] |
| Dexamethasone |
DMMWZET
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Dexamethasone. |
Rheumatoid arthritis [FA20]
|
[42] |
| Sarilumab |
DMOGNXY
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Sarilumab. |
Rheumatoid arthritis [FA20]
|
[39] |
| Leflunomide |
DMR8ONJ
|
Major |
Increased risk of hepatotoxicity by the combination of Methotrexate and Leflunomide. |
Rheumatoid arthritis [FA20]
|
[53] |
| Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Methotrexate when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[76] |
| Tedizolid |
DMG2SKR
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Tedizolid. |
Skin and skin-structure infection [1F28-1G0Z]
|
[39] |
| Larotrectinib |
DM26CQR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Larotrectinib. |
Solid tumour/cancer [2A00-2F9Z]
|
[39] |
| Methylprednisolone |
DM4BDON
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Methylprednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[42] |
| PDX-101 |
DM6OC53
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and PDX-101. |
Solid tumour/cancer [2A00-2F9Z]
|
[39] |
| Trabectedin |
DMG3Y89
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[39] |
| Prednisolone |
DMQ8FR2
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[42] |
| Methyltestosterone |
DMWLFGO
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Methyltestosterone. |
Solid tumour/cancer [2A00-2F9Z]
|
[39] |
| Disulfiram |
DMCL2OK
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Disulfiram. |
Substance abuse [6C40]
|
[39] |
| Naltrexone |
DMUL45H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Naltrexone. |
Substance abuse [6C40]
|
[39] |
| Fostamatinib |
DM6AUHV
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Fostamatinib. |
Thrombocytopenia [3B64]
|
[39] |
| Eltrombopag |
DMOGFIX
|
Moderate |
Decreased clearance of Methotrexate due to the transporter inhibition by Eltrombopag. |
Thrombocytopenia [3B64]
|
[77] |
| Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Lenvatinib. |
Thyroid cancer [2D10]
|
[39] |
| Methimazole |
DM25FL8
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Methimazole. |
Thyrotoxicosis [5A02]
|
[39] |
| Tizanidine |
DMR2IQ4
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Tizanidine. |
Tonus and reflex abnormality [MB47]
|
[39] |
| Trimetrexate |
DMDEA85
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Trimetrexate. |
Toxoplasmosis [1F57]
|
[39] |
| Sirolimus |
DMGW1ID
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Sirolimus. |
Transplant rejection [NE84]
|
[73] |
| Azathioprine |
DMMZSXQ
|
Minor |
Decreased metabolism of Methotrexate caused by Azathioprine. |
Transplant rejection [NE84]
|
[63] |
| Tacrolimus |
DMZ7XNQ
|
Major |
Increased risk of nephrotoxicity by the combination of Methotrexate and Tacrolimus. |
Transplant rejection [NE84]
|
[73] |
| Olsalazine |
DMZW9HA
|
Moderate |
Increased risk of nephrotoxicity by the combination of Methotrexate and Olsalazine. |
Ulcerative colitis [DD71]
|
[55] |
| Nitrofurantoin |
DM7PQIK
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Nitrofurantoin. |
Urinary tract infection [GC08]
|
[39] |
| Sulfamethizole |
DMGCHDS
|
Moderate |
Increased plasma concentration of Methotrexate and Sulfamethizole due to competitive binding of plasma proteins. |
Urinary tract infection [GC08]
|
[44] |
| Plazomicin |
DMKMBES
|
Moderate |
Increased risk of nephrotoxicity by the combination of Methotrexate and Plazomicin. |
Urinary tract infection [GC08]
|
[37] |
| Carbenicillin |
DMLEDNK
|
Major |
Decreased elimination of Methotrexate caused by Carbenicillin mediated competitive inhibition of renal tubular secretion. |
Urinary tract infection [GC08]
|
[43] |
| Mezlocillin |
DMY5JEP
|
Major |
Decreased elimination of Methotrexate caused by Mezlocillin mediated competitive inhibition of renal tubular secretion. |
Urinary tract infection [GC08]
|
[43] |
| Elagolix |
DMB2C0E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Methotrexate and Elagolix. |
Uterine fibroid [2E86]
|
[39] |
| Triamcinolone |
DM98IXF
|
Moderate |
Additive immunosuppressive effects by the combination of Methotrexate and Triamcinolone. |
Vasomotor/allergic rhinitis [CA08]
|
[42] |
| Ganciclovir |
DM1MBYQ
|
Moderate |
Additive myelosuppressive effects by the combination of Methotrexate and Ganciclovir. |
Virus infection [1A24-1D9Z]
|
[37] |
| Valaciclovir |
DMHKS94
|
Moderate |
Increased risk of nephrotoxicity by the combination of Methotrexate and Valaciclovir. |
Virus infection [1A24-1D9Z]
|
[39] |
| Valganciclovir |
DMS2IUH
|
Moderate |
Additive myelosuppressive effects by the combination of Methotrexate and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[37] |
| ----------- |
|
|
|
|
|
